NASDAQ:HURA TuHURA Biosciences Q3 2025 Earnings Results & Report $1.41 +0.01 (+0.71%) As of 01:26 PM Eastern This is a fair market value price provided by Massive. Learn more. TuHURA Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.14 versus the -$0.15 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call7:00 AM ET TuHURA Biosciences EPS ResultsActual EPS-$0.14Consensus EPS -$0.15Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersTuHURA Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TuHURA Biosciences Q3 2025 Earnings FAQ Did TuHURA Biosciences beat earnings estimates for Q3 2025? TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.14 per share for Q3 2025, beating the consensus estimate of -$0.15. The report was announced on Friday, November 14, 2025. TuHURA Biosciences Earnings HeadlinesTuHURA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14, 2026 | marketscreener.comMTuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateNovember 13, 2026 | prnewswire.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 18 at 1:00 AM | Profits Run (Ad)TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and ExpositionNovember 4, 2026 | prnewswire.comTuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated ...October 26, 2026 | finance.yahoo.comTuHURA Biosciences Adds Borrowing Under Credit FacilityOctober 16, 2026 | tipranks.comSee More TuHURA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email. Email Address About TuHURA BiosciencesTuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development. TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.View TuHURA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles General Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a BreakoutAmazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.